Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic Fibrosis

NCT06371261 | Active Not Recruiting

• 1 other identifier: 2023/CHU/07
• Study Type: observational
• Target: 17
• Locations: 1 country
• Sites: 2

Brief Summary

The pathogenicity of Achromobacter bacteria is not yet well established, but studies show a decline in respiratory function and an increase in mortality associated with chronic colonisation, making it possible to classify the Achromobacter genus as an emerging pathogen in cystic fibrosis. It is possible that certain species or clones are more virulent or resistant, requiring the adaptation of measures to prevent cross-transmission in the centres concerned. However, until now, the identification of Achromobacter species has involved the use of molecular biology techniques that are not routinely applicable in diagnostic laboratories, limiting studies and the collection of epidemiological data. Recently, a database using MALDI-TOF mass spectrometry has been built for rapid and accurate species identification. In view of the local epidemiology and the current lack of data, it would be necessary and interesting to use this tool to study a cohort of cystic fibrosis patients in Réunion island (North and South sites) to see whether one species has a greater clinical impact than another (pathogenicity), and/or is more responsible for chronic colonisation.

Conditions

Cystic Fibrosis

Keywords

Achromobacter species; MALDI-TOF mass spectrometry; Réunion Island

Outcome Measures

Primary Outcomes (1)

• Frequency of pulmonary exacerbations according to the species of the Achromobacter genus colonising/infecting cystic fibrosis patients.

  The occurrence of pulmonary exacerbations as a function of the species of the genus Achromobacter spp. Colonising/infecting patients.

  2 years

Secondary Outcomes (5)

• Frequency of pulmonary exacerbations as a function of Achromobacter spp. colonisation status.

  2 years

• Emergence or existing presence of clones within the species of the genus Achromobacter circulating among cystic fibrosis patients in Réunion, using genomic analyses.

  2 years

• Presence of virulence factors in these strains using genomic analyses

  2 years

• Search for genes responsible for antibiotic resistance by genomic analysis of these strains

  2 years

• To describe the epidemiology of Achromobacter spp. in cystic fibrosis patients in Réunion

  2 years

Interventions

Biological analyses OTHER

A cytobacteriological examination of the sputum will be carried out and sent to the microbiology laboratory at the University Hospital of La Réunion. The micro-organisms will be quantified. The micro-organisms, and more specifically bacteria of the Achromobacter genus, will be identified by MALDI-TOF mass spectrometry using the published database (Garrigos et al.2021).

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Cohort of cystic fibrosis patients from Reunion island with Achromobacter spp colonisation

You may qualify if:

• Minor or major cystic fibrosis patients
• Patients living in La Réunion island.
• Patients for whom a non-opposition was obtained orally (if applicable from both one of the child's legal guardians and the child him/herself)

You may not qualify if:

• Patients without cystic fibrosis.

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Réunion: lead

Study Sites (2)

CHU la Réunion North

Saint-Denis, Reunion

Location

CHU la Réunion South

Saint-Pierre, Reunion

Location

MeSH Terms

Conditions

Cystic Fibrosis

Interventions

Biological Oxygen Demand Analysis

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases

Intervention Hierarchy (Ancestors)

Environmental Monitoring; Environmental Exposure; Environmental Pollution; Public Health; Environment and Public Health; Public Health Practice

Study Officials

• Thomas GARRIGOS, Pharm D, PhD

  CHU La Réunion

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2024
• First Posted: April 17, 2024
• Study Start: March 12, 2024
• Primary Completion (Estimated): March 19, 2027
• Study Completion (Estimated): March 19, 2027
• Last Updated: May 4, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

RE (2)